

REVIEW OF DECISIONS

PROGRAMME AND POLICY COMMITTEE MEETING
25-26 October 2016, GENEVA



Reach every child

www.gavi.org

DECISION 1: UPDATE ON COUNTRY PROGRAMMES

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

Find that exceptional circumstances in South Sudan and Yemen justify the continuation of Gavi support in those countries irrespective of their default status on their 2015 co-financing obligations.

DECISION 2: UPDATE ON COUNTRY PROGRAMMES: COUNTRY ENGAGEMENT FRAMEWORK (1/2)

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** certain adjustments to the existing methods of reviewing and approving new Gavi support to facilitate and inform a learning agenda for an updated review and approval process, including:
- i. offering opportunities for review of new Gavi support on a country-by-country basis and outside of the existing IRC schedule;
 - ii. enabling IRC members and other impartial technical experts with local/regional expertise to serve in the capacity as independent reviewers as long as there is no conflict of interest;

DECISION 2: UPDATE ON COUNTRY PROGRAMMES: COUNTRY ENGAGEMENT FRAMEWORK (2/2)

- iii. leveraging engagement of country stakeholders to provide input and immediately address issues flagged by the reviewers; and
 - iv. consider, for those countries with relatively smaller Gavi investments, the use of existing review mechanisms such as the HLRP (or the subset of IRC members of the HLRP) to provide funding recommendations on new as well as existing Gavi support.
- b) **Note** the outcome of this process will allow a final design to be presented to the PPC and Board by end 2017.

DECISION 3: COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (1/3)

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

a) **Note** that:

i. In June 2015 it

- a) **Approved** *the creation of an innovative mechanism to strengthen country cold chain systems and advance the Alliance's Supply Chain Strategy and, ultimately, its coverage and equity goals (the «CCE platform»), the design of which is set out in Section 3 of Doc 15 to the PPC and includes a funding model tiered by country GNI level;*
- b) **Noted** *that an amount of US\$ 50 million (to be reassessed and potentially increased based on initial applications to the CCE platform) will be allocated from the resources pledged for 2016-2020 (which envisage funding for strategic initiatives to realise Gavi's new strategy) to launch the implementation of the CCE platform and fund the initial applications in 2016-2017 and requested the Secretariat to report back to the PPC and to the Board in 2017 on the implementation of the CCE platform;*

DECISION 3: COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (2/3)

- ii. At that time, the Secretariat noted that the proposed initial investment of US\$ 50 million by Gavi is to launch the platform. The total estimated funding for the platform required for Gavi countries, excluding India, was estimated to be between US\$ 240 million and US\$ 310 million for five years;
- iii. Following the approval of the CCE platform and its subsequent launch, demand for support under the platform has exceeded initial expectations foreseen in the 2015 CCE platform Board decision;
- iv. Additional funding is now required for 20 countries that have applied in 2016 for an amount of approximately US \$150 million; and
- v. Additional applications are expected to be received before the first Board meeting in June 2017.

DECISION 3: COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (3/3)

b) Decide that:

- i. Consistent with the 2015 Board decision, a review of progress and lessons learned of the CCE platform should be presented to the PPC at its meeting in May 2017 and the Board in June 2017, including its links with HSIS, anticipated impact on the market and the quality of the overall immunisation systems, country case studies, an updated demand forecast, and taking into account feedback provided by the IRC on applications reviewed;
- ii. Based on that review, the Secretariat will present to the PPC and Board future options for the implementation of the CCEOP; and
- iii. In the period up to the Board meeting in June 2017, the total multi-year commitments of grants for CCEOP should not exceed US\$ 250 million, requesting the Secretariat to develop strategies for equitable allocation of the funds available.

DECISION 4: FRAGILE SETTINGS AND EMERGENCIES

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

Approve the principles for Gavi's approach to classifying and responding to fragile and emergency settings as embodied in sections 3, 4 and 5 in Doc 07, and request the Secretariat to operationalise these principles into a policy which will replace the 2012 Fragility and Immunisation Policy.

DECISION 5: SYRIA

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it **approve** one of the following options for engagement in Syria:

- i. **Option 1 – No engagement**
- ii. **Option 2 – Limited and temporary support.** An initial, time-limited commitment to support vaccine procurement only (option 2A) or vaccine and cold chain procurement (option 2B); to be reviewed 2 years from now.
- iii. **Option 3 – Comprehensive, needs-based support, similar to “normal” eligibility.** A more open-ended commitment to start engagement in Syria now with needs to be reviewed on a rolling basis. Support would end if Syria would get a GNI p.c. estimate above Gavi’s threshold, be classified as a UMIC or be downgraded to a level 2 emergency. Support may include vaccines, cold chain and HSIS.

DECISION 6: GAVI'S SUPPORT FOR EMERGENCY VACCINE STOCKPILES

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** the principles set out in Figure 2 of Doc 08 for Gavi's support for emergency stockpiles of Gavi-supported vaccines as an integral part of integrated disease control strategies, as amended by discussions at the PPC, overriding previous Board decisions on Gavi's support for emergency stockpiles; and
- b) **Note** that additional funding associated with the adoption of the principles for the period 2017-2020 amount to approximately US\$ 86 million for meningitis and cholera.

DECISION 7: GAVI'S CONTINUED ROLE IN YELLOW FEVER CONTROL

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Agree** that Gavi's support for Yellow Fever vaccine be based on the Eliminating Yellow Fever Epidemics Strategy developed by WHO (the "EYE Strategy").
- b) **Note** that due to increased supply availability, and the identified need to improve Yellow Fever vaccine coverage in endemic countries, to introduce forecasted expenditure on Yellow Fever vaccine support in Gavi eligible countries in the period 2017-2020 will increase by approximately up to US\$ 150 million.

DECISION 8: REVIEW OF GAVI SUPPORT FOR HPV VACCINE

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** that for HPV vaccine countries can apply:
- i. directly for national introduction, while maintaining the option of implementing a phased national introduction;
 - ii. for support for multi-age cohort HPV vaccinations (9-14 years of age) in year one of introduction of the vaccine, including support for 100% of vaccine costs for the additional cohorts, and operational support of up to US\$ 0.65 per targeted girl of those cohorts.
- (b) **Note** that the additional funding associated with the above approval for the period 2016-2020 is expected to be approximately US\$ 72 million.

